Could filtered blood transfusions shield cancer Patients' immune systems?

NCT ID NCT00180869

NEW Completed Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This trial asks whether the type of red blood cell transfusion given during cancer surgery affects the body's immune response. It compares standard transfusions with leuko-reduced ones, which have white blood cells removed. The study involves 150 cancer patients undergoing curative surgery with a high chance of needing a transfusion. Researchers will measure immune markers and track infections and survival to see if one approach is gentler on the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two types of red blood cell transfusions: unmodified (standard) and leuko-reduced (filtered to remove white blood cells)
What this could lead to: If one transfusion type proves less disruptive to the immune system, it could lead to better recovery and fewer infections after cancer surgery.
What could go wrong: This is a mid-stage trial with 150 participants, so results may not apply to all patients. The immune effects measured are early indicators, not proof of long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SURGERY

Contacts and locations

Locations

Institut Gustave Roussy

Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.